查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
青光眼治疗药的全球市场(2025年):2024年～2030年的分析
市场调查报告书
商品编码
1700500

青光眼治疗药的全球市场(2025年):2024年～2030年的分析

2025 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2024 to 2030
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

新到信息

全球青光眼药物市场（2025 年）包括新的区域销售预测，其中考虑到美元兑其他主要货币的走强，以及对青光眼盛行率和诊断的最新分析。

报告还提供了美国和日本仿製药和原研药按药品类别划分的市场占有率分析、美国和西欧按一线和伴随药物划分的处方分层，以及西欧眼科医生对药物输送持久性的调查数据。

我们也提供最新的青光眼药物管道分析、正在进行的临床试验的最新情况以及区域经济指标的回顾。

《全球青光眼药物市场（2025 年）》分析了全球和区域青光眼药物市场，强调了未来成功的主要趋势和关键推动因素。本报告对品牌前列腺素、仿製前列腺素、β受体阻断剂、碳酸酐酶抑制剂、α激动剂、固定组合药物、NO供体和Rho激酶抑制剂进行了2030年的预测。该报告还涵盖了目前正在开发的 30 多种候选药物，并对管道产品进行了广泛的讨论。此外，报告还介绍了25家青光眼製药公司，讨论了它们的产品、战略市场地位、背景和前景。

内容

本报告分析了目前的青光眼药物市场，并预测了未来五年的市场表现。全球市场分析基于八个区域/经济类别（美国、西欧、日本、其他富裕国家、中国、印度、拉丁美洲和世界其他地区），也用于提供全球疾病盛行率预测。此外，该报告还探讨了有关疾病过程、青光眼人群、青光眼治疗和其他各种主题的数据和信息，为读者理解这一眼科领域提供深度和背景。

主要内容

  • 青光眼的类型和风险因素
  • 疾病的诊断与治疗
  • 青光眼医疗保健提供者（包括眼科医师和视光师）的全球视角
  • 全球疾病流行预测（5年）
  • 市面上的青光眼药物及其作用机制
  • 仿製药与品牌药及其对市场的影响
  • 青光眼药物研发管线
  • 生产和销售青光眼治疗药物的公司简介
简介目录

What's New:

The "2025 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts that consider appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma.

The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan, prescription stratification by first-line and adjunctive use in the United States and Western European countries, and survey data on Western European ophthalmologists' plans for sustained drug delivery.

It also provides updated analysis of the glaucoma pharmaceutical pipeline, gives updates on ongoing clinical trials, and reviews regional economic indicators.

The "2025 Glaucoma Pharmaceuticals Market Report" analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2030 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 25 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

Coverage includes:

  • Types of glaucoma and risk factors.
  • Diagnosis and treatment of the disease.
  • A global view of glaucoma care providers, including ophthalmologists and optometrists.
  • Current estimates and five-year forecasts for disease prevalence worldwide.
  • Glaucoma medications in the marketplace and their mechanisms of action.
  • Discussion of generic versus branded drugs and their market impact.
  • The development pipeline for glaucoma pharmaceuticals.
  • Profiles of companies making and marketing glaucoma medications.